

# Samuel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5482530/publications.pdf>

Version: 2024-02-01

244  
papers

27,002  
citations

28190

55  
h-index

5965

160  
g-index

244  
all docs

244  
docs citations

244  
times ranked

21945  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 131-141. | 1.8 | 55        |
| 2  | Profile of Patients with Isolated Distal Deep Vein Thrombosis versus Proximal Deep Vein Thrombosis or Pulmonary Embolism: RE-COVERY DVT/PE Study. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 446-458.                              | 1.5 | 15        |
| 3  | Safety and effectiveness of dabigatran in routine clinical practice: the RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 399-409.  | 1.0 | 3         |
| 4  | Acute Management of High-Risk and Intermediate-Risk Pulmonary Embolism in Children. <i>Chest</i> , 2022, 161, 791-802.   | 0.4 | 15        |
| 5  | Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in Patients with Provoked Venous Thromboembolism and Enduring Risk Factors: Rationale and Design of the HI-PRO Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1061-1070.   | 1.8 | 4         |
| 6  | Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. <i>Thrombosis Research</i> , 2022, 211, 63-69.                                      | 0.8 | 1         |
| 7  | Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol. <i>BMJ Open</i> , 2022, 12, e060000.   | 0.8 | 11        |
| 8  | Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.                          | 0.8 | 3         |
| 9  | Early Detection and Management of Venous Thrombosis in Skull Base Surgery: Role of Routine Doppler Ultrasound Monitoring. <i>Neurosurgery</i> , 2022, 91, 115-122.   | 0.6 | 1         |
| 10 | Sex Differences in PrEsentation, Risk Factors, Drug and Interventional Therapies, and OUtcomes of Elderly PatientS with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.       | 0.8 | 3         |
| 11 | Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.              | 1.2 | 59        |
| 12 | Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants. <i>JAMA Cardiology</i> , 2022, 7, 747.  | 3.0 | 15        |
| 13 | Temporal trends in abdominal aortic aneurysmal disease: a nationwide cohort study on cardiovascular morbidity and medical cardioprotective therapy. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1957-1964.                      | 0.8 | 8         |
| 14 | Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 281-290.                              | 1.0 | 2         |
| 15 | Evaluation and optimization of prescribed concomitant antiplatelet and anticoagulation therapy centrally managed by an anticoagulation management service. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 405-412.                    | 1.0 | 3         |
| 16 | Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000â€“18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.          | 5.2 | 100       |
| 17 | Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. <i>Oncologist</i> , 2021, 26, e8-e16.                                      | 1.9 | 31        |
| 18 | Profile of patients diagnosed with acute venous thromboembolism in routine practice according to age and renal function: RE-COVERY DVT/PE study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 561-570.                              | 1.0 | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE. <i>TH Open</i> , 2021, 05, e24-e34.   | 0.7 | 16        |
| 20 | Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110379.   | 0.7 | 1         |
| 21 | PREVENTion of CLots in Orthopaedic Trauma (PREVENT CLOT): a randomised pragmatic trial protocol comparing aspirin versus low-molecular-weight heparin for blood clot prevention in orthopaedic trauma patients. <i>BMJ Open</i> , 2021, 11, e041845.   | 0.8 | 14        |
| 22 | Extended duration venous thromboembolism prophylaxis with betrixaban for patients re-admitted with venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 22-29.  | 1.0 | 0         |
| 23 | Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1903-1921.   | 1.2 | 150       |
| 24 | Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1620. | 3.8 | 515       |
| 25 | Stroke risk factors and outcomes among hospitalized women with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1023-1031.   | 1.0 | 1         |
| 26 | Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. <i>Journal of the American Heart Association</i> , 2021, 10, e021117.   | 1.6 | 13        |
| 27 | Cerebral Venous Sinus Thrombosis in the U.S. Population, After Adenovirus-Based SARS-CoV-2 Vaccination, and After COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 408-411.  | 1.2 | 44        |
| 28 | Images in Vascular Medicine: Pulmonary embolism and acute aortic syndromes – “Double trouble when vascular medicine emergencies meet. <i>Vascular Medicine</i> , 2021, , 1358863X2110296.  | 0.8 | 0         |
| 29 | The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 203, 155-162.  | 0.8 | 9         |
| 30 | Impact of Atrial Fibrillation on In-Hospital Mortality and Stroke in Acute Aortic Syndromes. <i>American Journal of Medicine</i> , 2021, 134, 1419-1423.   | 0.6 | 2         |
| 31 | Loss of Pulmonary Vascular Volume as a Predictor of Right Ventricular Dysfunction and Mortality in Acute Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012347.   | 1.3 | 9         |
| 32 | Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3080-3089.   | 1.9 | 13        |
| 33 | Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism. <i>Journal of the American Heart Association</i> , 2021, 10, e021467.  | 1.6 | 4         |
| 34 | Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3031-3043.   | 1.9 | 14        |
| 35 | Association of ABO blood group type with cardiovascular events in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 584-586.   | 1.0 | 14        |
| 36 | Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.   | 1.2 | 42        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Catheter-directed thrombolysis for deep vein thrombosis: 2021 update. <i>Vascular Medicine</i> , 2021, 26, 662-669.  | 0.8 | 15        |
| 38 | Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. <i>Journal of Thrombosis and Haemostasis</i> , 2021, , .   | 1.9 | 8         |
| 39 | Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2021, 20, 103-107.   | 0.2 | 1         |
| 40 | Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). <i>European Heart Journal</i> , 2020, 41, 1086-1096.   | 1.0 | 35        |
| 41 | Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.   | 1.0 | 6         |
| 42 | 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). <i>European Heart Journal</i> , 2020, 41, 543-603.  | 1.0 | 2,426     |
| 43 | Venous Thromboembolism in Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 159-162.  | 1.2 | 18        |
| 44 | Selection Bias, Orthopaedic Style. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 631-633.   | 1.4 | 10        |
| 45 | Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 8-23.e18.   | 0.9 | 55        |
| 46 | New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309. | 1.4 | 29        |
| 47 | ECMO and Surgical Embolectomy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 912-915.   | 1.2 | 3         |
| 48 | Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. <i>American Journal of Cardiology</i> , 2020, 133, 175-178.  | 0.7 | 4         |
| 49 | Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 158-160.   | 1.0 | 0         |
| 50 | Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2060-2072.  | 1.2 | 230       |
| 51 | Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease. <i>JAMA Network Open</i> , 2020, 3, e2022886.   | 2.8 | 28        |
| 52 | Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. <i>Critical Pathways in Cardiology</i> , 2020, 19, 178-186.   | 0.2 | 1         |
| 53 | Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative. <i>American Journal of Medicine</i> , 2020, 133, 1-27.   | 0.6 | 18        |
| 54 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.   | 1.8 | 206       |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Predictors of Treatment Response Following Ultrasound-Facilitated Catheter-Directed Thrombolysis for Submassive and Massive Pulmonary Embolism. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008747.                                      | 1.4 | 8         |
| 56 | Thromboembolism Prophylaxis for Patients Discharged From the Hospital. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3148-3150.   | 1.2 | 6         |
| 57 | Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. <i>Thrombosis and Haemostasis</i> , 2020, 120, 924-936.   | 1.8 | 12        |
| 58 | External validation of the SOXâ€PTS score in a prospective multicenter trial of patients with proximal deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1381-1389.   | 1.9 | 9         |
| 59 | Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism. <i>Thrombosis Research</i> , 2020, 186, 78-79.   | 0.8 | 2         |
| 60 | COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2950-2973.   | 1.2 | 2,392     |
| 61 | Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. <i>British Journal of Haematology</i> , 2020, 190, 555-561.  | 1.2 | 36        |
| 62 | Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PEâ„¢ Study. <i>American Journal of Medicine</i> , 2020, 133, 936-945.   | 0.6 | 10        |
| 63 | Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. <i>Thrombosis Research</i> , 2020, 196, 382-394. | 0.8 | 62        |
| 64 | Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 908-918.   | 1.5 | 13        |
| 65 | Netâ€clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.   | 1.9 | 5         |
| 66 | Collaborative Cardiology and Pulmonary Management of Pulmonary Hypertension. <i>Chest</i> , 2019, 156, 200-202.  | 0.4 | 3         |
| 67 | Pulmonary Embolism Hospitalization, Readmission, and Mortality Rates in US Older Adults, 1999-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 574.  | 3.8 | 69        |
| 68 | Isolated Distal Deep Vein Thrombosis: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1675-1685.   | 1.8 | 34        |
| 69 | Pulmonary Embolism in Patients Withâ€Syncope. <i>Journal of the American College of Cardiology</i> , 2019, 74, 755-758.  | 1.2 | 3         |
| 70 | Use of Prophylaxis for Prevention of Venous Thromboembolism in Patients with Isolated Foot or Ankle Surgery: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1686-1694.  | 1.8 | 8         |
| 71 | Peripheral Artery Disease: Past, Present, and Future. <i>American Journal of Medicine</i> , 2019, 132, 1133-1141.  | 0.6 | 123       |
| 72 | Thromboprophylaxis Strategies in Acute Medically Ill Patients. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 118-126.  | 0.6 | 0         |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 73 | Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. <i>Vascular Medicine</i> , 2019, 24, 442-451.  | 0.8  | 35        |
| 74 | Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961988000.                                     | 0.7  | 7         |
| 75 | Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961987603.                   | 0.7  | 20        |
| 76 | Fine-tuning the decision to initiate anticoagulation in atrial fibrillation by accounting for age and cardiovascular comorbidities. <i>European Heart Journal</i> , 2019, 40, 1515-1517.   | 1.0  | 2         |
| 77 | Pharmacomechanical Catheter-Directed Thrombolysis in Acute Femoralâ€“Popliteal Deep Vein Thrombosis: Analysis from a Stratified Randomized Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 633-644.  | 1.8  | 44        |
| 78 | Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELDâ€“VTE patients. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1694-1706.   | 1.9  | 30        |
| 79 | Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.   | 1.8  | 28        |
| 80 | Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.  | 0.7  | 1         |
| 81 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 45.  | 1.3  | 22        |
| 82 | How the Results of a Randomized Trial of Catheter-Directed Thrombolysis Versus Anticoagulation alone for Submassive Pulmonary Embolism Would Affect Patient and Physician Decision Making: Report of an Online Survey. <i>Journal of Clinical Medicine</i> , 2019, 8, 215. | 1.0  | 2         |
| 83 | Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. <i>Circulation</i> , 2019, 139, 1234-1236.  | 1.6  | 7         |
| 84 | Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. <i>Intensive Care Medicine</i> , 2019, 45, 477-487.   | 3.9  | 17        |
| 85 | Quantification and Significance of Pulmonary Vascular Volume in Predicting Response to Ultrasound-Facilitated, Catheter-Directed Fibrinolysis in Acute Pulmonary Embolism (SEATTLE-3D). <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e009903.                    | 1.3  | 13        |
| 86 | Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.   | 1.8  | 76        |
| 87 | Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. <i>New England Journal of Medicine</i> , 2019, 380, 752-762.   | 13.9 | 886       |
| 88 | Fatal warfarin-associated intracranial hemorrhage in atrial fibrillation inpatients. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 331-335.  | 1.0  | 3         |
| 89 | Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism. <i>JAMA Internal Medicine</i> , 2019, 179, 263.   | 2.6  | 9         |
| 90 | Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. <i>Circulation</i> , 2019, 139, 1162-1173.   | 1.6  | 196       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 91  | Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019, 94, 21-28. | 2.0  | 50        |
| 92  | Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. <i>American Journal of Medicine</i> , 2018, 131, 972.e1-972.e7.                             | 0.6  | 29        |
| 93  | Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. <i>Circulation</i> , 2018, 137, 91-94.           | 1.6  | 27        |
| 94  | Expanding anticoagulation management services to include direct oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 274-280.   | 1.0  | 26        |
| 95  | Catheter-directed, ultrasound-facilitated fibrinolysis in obese patients with massive and submassive pulmonary embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 257-263.                 | 1.0  | 5         |
| 96  | Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.   | 1.2  | 19        |
| 97  | A Review of Thrombolysis in Venous Thromboembolism With an Analysis of Alteplase Admixture Stability. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 54-61.                              | 0.6  | 3         |
| 98  | Pharmacomechanical Therapy for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2018, 378, 1752-1753.   | 13.9 | 2         |
| 99  | Risk Stratification Model: Lower-Extremity Ultrasonography for Hospitalized Patients with Suspected Deep Vein Thrombosis. <i>Journal of General Internal Medicine</i> , 2018, 33, 21-25.                    | 1.3  | 6         |
| 100 | Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 1-8.              | 1.0  | 14        |
| 101 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2018, 118, 2046-2052.                                    | 1.8  | 48        |
| 102 | Let's Stop Dichotomizing Venous Thromboembolism as Provoked or Unprovoked. <i>Circulation</i> , 2018, 138, 2591-2593.   | 1.6  | 22        |
| 103 | Anticoagulation and Mortality Rates among Hospitalized Patients with Atrial Fibrillation. <i>TH Open</i> , 2018, 02, e33-e38.   | 0.7  | 7         |
| 104 | Antiplatelet Prescription in Atrial Fibrillation: Association with a Low Rate of Anticoagulation. <i>TH Open</i> , 2018, 02, e229-e232.   | 0.7  | 2         |
| 105 | Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018, 02, e16-e24.   | 0.7  | 8         |
| 106 | Dementia and Atrial Fibrillation: Pathophysiological Mechanisms and Therapeutic Implications. <i>American Journal of Medicine</i> , 2018, 131, 1408-1417.   | 0.6  | 34        |
| 107 | Cautionary Notes About Outpatient Treatment of Acute Pulmonary Embolism. <i>Chest</i> , 2018, 154, 233-234.   | 0.4  | 3         |
| 108 | Type 1 versus type 2 diabetes and thromboembolic risk in patients with atrial fibrillation: A Danish nationwide cohort study. <i>International Journal of Cardiology</i> , 2018, 268, 137-142.              | 0.8  | 22        |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1401-1410.   | 1.1 | 280       |
| 110 | Nursing Home Residents with Venous Thrombosis: A Vulnerable, Fragile and Disenfranchised Population. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1507-1508.  | 1.8 | 1         |
| 111 | Heparin-Induced Thrombocytopenia in Healthy Individuals with Continuous Heparin Infusion. <i>TH Open</i> , 2018, 02, e49-e53.   | 0.7 | 0         |
| 112 | Computed tomography angiography with pulmonary artery thrombus burden and right-to-left ventricular diameter ratio after pulmonary embolism. <i>Vascular</i> , 2017, 25, 54-62.   | 0.4 | 6         |
| 113 | Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw281.  | 3.0 | 5         |
| 114 | Risk factors for major bleeding in the SEATTLE II trial. <i>Vascular Medicine</i> , 2017, 22, 44-50.  | 0.8 | 33        |
| 115 | Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVERÂ®, RE-COVERÂ®, II, and RE-MEDYÂ®,. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 484-489.   | 1.0 | 6         |
| 116 | Impact of gender on event rates at 1â€..year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. <i>BMJ Open</i> , 2017, 7, e014579.   | 0.8 | 30        |
| 117 | When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. <i>American Heart Journal</i> , 2017, 189, 1-8.                                      | 1.2 | 14        |
| 118 | Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis in elderly patients with pulmonary embolism: A SEATTLE II sub-analysis. <i>Vascular Medicine</i> , 2017, 22, 324-330.  | 0.8 | 3         |
| 119 | Evaluation of a Device Combining an Inferior Venaâ€Cava Filter and a Central Venous Catheterâ€forâ€Preventing Pulmonary Embolism Among Critically Ill Trauma Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1248-1254. | 0.2 | 22        |
| 120 | PEITHO Long-Term Outcomes Study. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1545-1548.  | 1.2 | 13        |
| 121 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Ove<br><i>Journal</i> , 2017, 185, 93-100.  | 1.2 | 48        |
| 122 | Competing risk analysis in a large cardiovascular clinical trial: An <scp>APEX</scp> substudy. <i>Pharmaceutical Statistics</i> , 2017, 16, 445-450.  | 0.7 | 8         |
| 123 | N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.                                     | 1.0 | 11        |
| 124 | Inferior Vena Cava Filters to Prevent Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1587-1597.   | 1.2 | 134       |
| 125 | Giants in Chest Medicine. <i>Chest</i> , 2017, 152, 463-465.  | 0.4 | 0         |
| 126 | Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .                  | 1.6 | 40        |



| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 127 | The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65.  | 0.7  | 94        |
| 128 | Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. <i>New England Journal of Medicine</i> , 2017, 377, 2240-2252.  | 13.9 | 557       |
| 129 | Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.   | 1.6  | 61        |
| 130 | Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.  | 1.8  | 22        |
| 131 | Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2045-2052.  | 1.8  | 36        |
| 132 | NOACs for treatment of venous thromboembolism in clinical practice. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1317-1325.   | 1.8  | 18        |
| 133 | More than an anticoagulant: Do heparins have direct anti-inflammatory effects?. <i>Thrombosis and Haemostasis</i> , 2017, 117, 437-444.   | 1.8  | 160       |
| 134 | RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2017, 117, 415-421.   | 1.8  | 14        |
| 135 | Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. <i>TH Open</i> , 2017, 01, e82-e91.  | 0.7  | 13        |
| 136 | Requiem for Liberalizing Indications for Vena Caval Filters?. <i>Circulation</i> , 2016, 133, 1992-1994.  | 1.6  | 9         |
| 137 | Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.   | 13.9 | 379       |
| 138 | Syncope (Fainting). <i>Circulation</i> , 2016, 133, e600-2.   | 1.6  | 14        |
| 139 | Women and Heart Attacks. <i>Circulation</i> , 2016, 133, e428-9.  | 1.6  | 5         |
| 140 | North American Thrombosis Forum, AF Action Initiative Consensus Document. <i>American Journal of Medicine</i> , 2016, 129, S1-S29.  | 0.6  | 24        |
| 141 | Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER <sup>Â</sup> , RE-COVER <sup>Â</sup> , II, and RE-MEDY <sup>Â</sup> . <i>Vascular Medicine</i> , 2016, 21, 506-514. | 0.8  | 71        |
| 142 | Treatment of acute pulmonary embolism with dabigatran versus warfarin. <i>Thrombosis and Haemostasis</i> , 2016, 116, 714-721.  | 1.8  | 24        |
| 143 | Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. <i>Vascular Medicine</i> , 2016, 21, 361-368.             | 0.8  | 15        |
| 144 | Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. <i>Vascular Medicine</i> , 2016, 21, 400-407.   | 0.8  | 44        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 145 | Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 787-794.  | 0.2 | 26        |
| 146 | Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. <i>American Journal of Medicine</i> , 2016, 129, 1198-1204.  | 0.6 | 121       |
| 147 | Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1027-1035.  | 1.2 | 61        |
| 148 | Warfarin and Vascular Calcification. <i>American Journal of Medicine</i> , 2016, 129, 635.e1-635.e4.   | 0.6 | 73        |
| 149 | Four key questions surrounding thrombolytic therapy for submassive pulmonary embolism. <i>Vascular Medicine</i> , 2016, 21, 47-52.   | 0.8 | 20        |
| 150 | Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 227-232.   | 1.0 | 9         |
| 151 | The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Trial. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 16, 3824-3824.  | 0.6 | 0         |
| 152 | A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis. <i>Journal of Visualized Experiments</i> , 2015, , e52761.   | 0.2 | 3         |
| 153 | Venous thromboembolism: an ounce of prevention is worth a pound of cure. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1174-1175.   | 1.8 | 0         |
| 154 | Performance of Wells Score for Deep Vein Thrombosis in the Inpatient Setting. <i>JAMA Internal Medicine</i> , 2015, 175, 1112.   | 2.6 | 84        |
| 155 | Predictive Value of Computed Tomography in Acute Pulmonary Embolism: Systematic Review and Meta-analysis. <i>American Journal of Medicine</i> , 2015, 128, 747-759.e2.   | 0.6 | 231       |
| 156 | Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. <i>Annals of Thoracic Surgery</i> , 2015, 100, 1245-1252.  | 0.7 | 115       |
| 157 | Obstructive Sleep Apnea. <i>Circulation</i> , 2015, 132, e114-6.   | 1.6 | 4         |
| 158 | A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1382-1392.              | 1.1 | 648       |
| 159 | Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. <i>Hospital Practice (1995)</i> , 2015, 43, 249-257.  | 0.5 | 24        |
| 160 | Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. <i>American Heart Journal</i> , 2015, 169, 186-187. | 1.2 | 9         |
| 161 | Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER® and RE-COVER II. <i>Blood</i> , 2015, 126, 4730-4730.   | 0.6 | 0         |
| 162 | Inflammation and Myocardial Infarction. <i>Circulation</i> , 2014, 130, e334-6.  | 1.6 | 16        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014, 167, 335-341.   | 1.2 | 81        |
| 164 | Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. <i>European Heart Journal</i> , 2014, 35, 1836-1843.  | 1.0 | 16        |
| 165 | Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis. <i>Circulation</i> , 2014, 129, 764-772.  | 1.6 | 824       |
| 166 | Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDYâ„¢. <i>Blood</i> , 2014, 124, 1544-1544.  | 0.6 | 9         |
| 167 | Post-Hoc Analysis of RE-MEDYâ„¢ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism. <i>Blood</i> , 2014, 124, 4270-4270.                              | 0.6 | 2         |
| 168 | Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVERâ„¢ and RE-COVERâ„¢ II. <i>Blood</i> , 2014, 124, 594-594.          | 0.6 | 7         |
| 169 | Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 371-374.   | 1.0 | 2         |
| 170 | Improving Clinician Performance of Inpatient Venous Thromboembolism Risk Assessment and Prophylaxis. <i>Hospital Practice (1995)</i> , 2013, 41, 123-131.  | 0.5 | 2         |
| 171 | Preventing DVT in Peripherally Inserted Central Catheters. <i>Chest</i> , 2013, 143, 589-590.  | 0.4 | 1         |
| 172 | Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 1136-1136.      | 0.6 | 6         |
| 173 | Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 212-212.                  | 0.6 | 10        |
| 174 | Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 2375-2375.                             | 0.6 | 10        |
| 175 | Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II. <i>Blood</i> , 2013, 122, 582-582.                   | 0.6 | 13        |
| 176 | Axial and Reformatted Four-Chamber Right Ventricleâ€”toâ€”Left Ventricle Diameter Ratios on Pulmonary CT Angiography as Predictors of Death After Acute Pulmonary Embolism. <i>American Journal of Roentgenology</i> , 2012, 198, 1353-1360. | 1.0 | 69        |
| 177 | Counterpoint: Should Coagulopathy Be Repaired Prior to Central Venous Line Insertion? No. <i>Chest</i> , 2012, 141, 1142-1144.   | 0.4 | 3         |
| 178 | Pulmonary embolism and deep vein thrombosis. <i>Lancet</i> , The, 2012, 379, 1835-1846.  | 6.3 | 809       |
| 179 | Venous thromboembolism: Epidemiology and magnitude of the problem. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 235-242.  | 0.7 | 176       |
| 180 | Antithrombotic Therapy for VTE Disease. <i>Chest</i> , 2012, 141, e419S-e496S.   | 0.4 | 3,745     |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 181 | Benefit of Extended Maintenance Therapy for Venous Thromboembolism with Dabigatran Etexilate Is Maintained Over 1 Year of Post-Treatment Follow-up. <i>Blood</i> , 2012, 120, 21-21.  | 0.6  | 20        |
| 182 | Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. <i>New England Journal of Medicine</i> , 2011, 365, 2167-2177.   | 13.9 | 512       |
| 183 | Peripherally Inserted Central Catheters. <i>Chest</i> , 2011, 140, 6-7.   | 0.4  | 7         |
| 184 | Optimal Duration of Anticoagulation After Venous Thromboembolism. <i>Circulation</i> , 2011, 123, 664-667.  | 1.6  | 26        |
| 185 | Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2011, 123, 1788-1830.  | 1.6  | 1,842     |
| 186 | A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II). <i>Blood</i> , 2011, 118, 205-205.   | 0.6  | 77        |
| 187 | Magnetic resonance angiography and venography were sensitive but had poor technical adequacy for diagnosing pulmonary embolism. <i>Annals of Internal Medicine</i> , 2010, 153, JCI.  | 2.0  | 1         |
| 188 | Pulmonary embolism in Black Americans. <i>American Journal of Hematology</i> , 2010, 85, 465-466.   | 2.0  | 3         |
| 189 | Eradication of hospital-acquired venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1089-1092.  | 1.8  | 10        |
| 190 | European Atherosclerosis Society Screening Recommendations for Lipoprotein(a) and High-Sensitivity C-Reactive Protein: Double Standard or Failure of Evidence-Based Medicine?. <i>Clinical Chemistry</i> , 2010, 56, 1544-1546. | 1.5  | 8         |
| 191 | Risk Factors for Venous Thromboembolism. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1-7.  | 1.2  | 456       |
| 192 | Comparison of ECG-gated versus non-gated CT ventricular measurements in thirty patients with acute pulmonary embolism. <i>International Journal of Cardiovascular Imaging</i> , 2009, 25, 101-107.                              | 0.7  | 57        |
| 193 | Cost-effectiveness of warfarin: Trial versus "real-world" stroke prevention in atrial fibrillation. <i>American Heart Journal</i> , 2009, 157, 1064-1073.   | 1.2  | 77        |
| 194 | Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2009, 361, 2342-2352.   | 13.9 | 2,330     |
| 195 | Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.. <i>Blood</i> , 2009, 114, 1-1.  | 0.6  | 7         |
| 196 | Pulmonary embolism diagnosis: remember the history and physical exam. <i>Thrombosis and Haemostasis</i> , 2009, 101, 7-8.   | 1.8  | 0         |
| 197 | Do take that break. <i>Harvard Business Review</i> , 2009, 87, 30, 128.   | 3.1  | 0         |
| 198 | Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 26, 35-40.   | 1.0  | 33        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Response to Letter Regarding Article, "Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Women's Health Study," <i>Circulation</i> , 2008, 117, . | 1.6  | 0         |
| 200 | Outpatient venous thromboembolism: the importance of optimum prophylaxis. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 12-13.  | 3.3  | 4         |
| 201 | Possible requiem: trial-and-error warfarin. <i>Blood</i> , 2007, 110, 1404-1405.   | 0.6  | 0         |
| 202 | Percutaneous mechanical thrombectomy for massive pulmonary embolism: Improve safety and efficacy by sharing information. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 807-808.                  | 0.7  | 9         |
| 203 | Venous thromboembolism risk among hospitalized patients: Magnitude of the risk is staggering. <i>American Journal of Hematology</i> , 2007, 82, 775-776.   | 2.0  | 18        |
| 204 | Low Intensity Warfarin Anticoagulation is Safe and Effective as a Long-Term Venous Thromboembolism Prevention Strategy. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 51-52.                               | 1.0  | 17        |
| 205 | Acute Pulmonary Embolism: Risk Stratification. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 153-156.                                 | 0.5  | 9         |
| 206 | Gastrointestinal Complications of Dual Antiplatelet Therapy. <i>Circulation</i> , 2006, 113, e655-8.   | 1.6  | 33        |
| 207 | How chest CT for the diagnosis of pulmonary embolism (PE) has changed my professional life: Reflections from a PE doctor. <i>Seminars in Roentgenology</i> , 2005, 40, 8-10.   | 0.2  | 9         |
| 208 | Thrombolytic Therapy for Patients With Pulmonary Embolism Who Are Hemodynamically Stable But Have Right Ventricular Dysfunction. <i>Archives of Internal Medicine</i> , 2005, 165, 2197.                               | 4.3  | 42        |
| 209 | Prevention of Venous Thromboembolism Among Hospitalized Medical Patients. <i>Circulation</i> , 2005, 111, e1-3.  | 1.6  | 50        |
| 210 | Case 17-2004. <i>New England Journal of Medicine</i> , 2004, 350, 2281-2290.   | 13.9 | 10        |
| 211 | Pulmonary Embolism After Coronary Artery Bypass Grafting. <i>Circulation</i> , 2004, 109, 2712-2715.   | 1.6  | 29        |
| 212 | Prevention of Recurrent Idiopathic Venous Thromboembolism. <i>Circulation</i> , 2004, 110, IV-20-IV-24.  | 1.6  | 20        |
| 213 | A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. <i>American Journal of Cardiology</i> , 2004, 93, 259-262.  | 0.7  | 452       |
| 214 | Prevention of Deep Vein Thrombosis and Pulmonary Embolism. <i>Circulation</i> , 2004, 110, e445-7.   | 1.6  | 39        |
| 215 | Pulmonary embolism. <i>Lancet, The</i> , 2004, 363, 1295-1305.   | 6.3  | 357       |
| 216 | Acute Pulmonary Embolism: Part I. <i>Circulation</i> , 2003, 108, 2726-2729.   | 1.6  | 362       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 217 | Acute Pulmonary Embolism: Part II. <i>Circulation</i> , 2003, 108, 2834-2838.   | 1.6  | 134       |
| 218 | DVT Prevention: What Is Happening in the "Real World"? <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 023-032.  | 1.5  | 20        |
| 219 | Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2003, 89, 953-8.   | 1.8  | 10        |
| 220 | Pulmonary Embolism and Deep Vein Thrombosis. <i>Circulation</i> , 2002, 106, 1436-1438.   | 1.6  | 65        |
| 221 | Thrombolysis for Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2002, 347, 1131-1132.   | 13.9 | 63        |
| 222 | Treatment of Blood Clots. <i>Circulation</i> , 2002, 106, e138-40.  | 1.6  | 16        |
| 223 | Echocardiography in the Management of Pulmonary Embolism. <i>Annals of Internal Medicine</i> , 2002, 136, 691.  | 2.0  | 407       |
| 224 | Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis. <i>Chest</i> , 2002, 122, 1933-1937.   | 0.4  | 181       |
| 225 | Normal d-dimer levels in emergency department patients suspected of acute pulmonary embolism. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1475-1478.                                       | 1.2  | 127       |
| 226 | Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>  | 0.7  | 20        |
| 227 | Unsolved Issues in the Treatment of Pulmonary Embolism. <i>Thrombosis Research</i> , 2001, 103, V245-V255.  | 0.8  | 9         |
| 228 | Thrombolysis in Pulmonary Embolism. <i>Circulation</i> , 2001, 104, 2876-2878.  | 1.6  | 44        |
| 229 | Prophylaxis of venous thrombosis. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 225-235.   | 0.4  | 7         |
| 230 | Epidemiology of Pulmonary Embolism. <i>Seminars in Vascular Medicine</i> , 2001, 01, 139-146.   | 2.1  | 21        |
| 231 | New Onset of Venous Thromboembolism Among Hospitalized Patients at Brigham and Women's Hospital Is Caused More Often by Prophylaxis Failure Than by Withholding Treatment. <i>Chest</i> , 2000, 118, 1680-1684. | 0.4  | 204       |
| 232 | Diagnosis of deep venous thrombosis. <i>Clinical Cornerstone</i> , 2000, 2, 29-35.  | 1.0  | 2         |
| 233 | Diagnosis of pulmonary embolism. <i>Clinical Cornerstone</i> , 2000, 2, 38-45.  | 1.0  | 6         |
| 234 | Management of deep venous thrombosis and pulmonary embolism. <i>Clinical Cornerstone</i> , 2000, 2, 47-55.  | 1.0  | 7         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 235 | The Approach to Massive Pulmonary Embolism. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2000, 21, 541-548.   | 0.8 | 4         |
| 236 | Deep venous thrombosis: early discharge strategies and outpatient management. , 1999, 7, 113-122.  |     | 13        |
| 237 | Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. <i>Journal of Thrombosis and Thrombolysis</i> , 1999, 8, 139-142. | 1.0 | 68        |
| 238 | Treatment of Pulmonary Thromboembolism.. <i>Internal Medicine</i> , 1999, 38, 620-625.   | 0.3 | 16        |
| 239 | Similarity in Presentation and Response to Thrombolysis Among Women and Men with Pulmonary Embolism. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 95-100.      | 1.0 | 5         |
| 240 | Deep Venous Thrombosis: Early Discharge Strategies and Outpatient Management. , 1997, 4, 365-374.  |     | 1         |
| 241 | Prospective Study of Moderate Alcohol Consumption and Risk of Peripheral Arterial Disease in US Male Physicians. <i>Circulation</i> , 1997, 95, 577-580.                   | 1.6 | 103       |
| 242 | Pulmonary Embolism Thrombolysis. <i>Circulation</i> , 1997, 96, 716-718.   | 1.6 | 64        |
| 243 | Factor V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism. <i>Circulation</i> , 1995, 92, 2800-2802.  | 1.6 | 208       |
| 244 | Tissue plasminogen activator and acute pulmonary embolism. <i>Journal of Cellular Biochemistry</i> , 1988, 38, 303-312.  | 1.2 | 5         |